Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Boehringer Ingelheim Animal Health USA, Inc. manufactures biological vaccines for animals. The firm specializes in pharmaceuticals for cattle, equine, pet, and swine. The company was founded by Albrecht Boehringer in 1885 and is headquartered in Duluth, GA.

Universiteit Utrecht Holding BV provides portfolio management and commercial development services. It strengthen and broaden cooperation among partners encompassing companies, governmental institutions, cultural and social organizations. The company was founded in 1996 and is headquartered in Utrecht, the Netherlands.

Celltrion Inc is a Korea-based company principally engaged in the research, development, and manufacture of therapeutic proteins. The company mainly manufactures biosimilar products, which are used to treat breast cancer, rheumatoid arthritis disease, Crohn's disease, Hodgkin's lymphoma, colorectal cancer, rheumatoid arthritis, respiratory syncytial virus, colon cancer, and others.

AbCellera is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic – and patients – sooner. With the integrated AbCellera platform, our experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set our partners up for enduring success.  We have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Oxford University Innovation is the University of Oxford's technology transfer company and manages the University's intellectual property portfolio, working with University researchers on identifying, protecting and marketing technologies through licensing, spin-out company formation and material sales. Oxford University Innovation also manages Oxford University Consulting, which arranges consulting services providing clients access to the expertise of the University's academics. Oxford University’s overarching Strategic Plan begins, “The University of Oxford aims to lead the world in research and education” immediately followed by, “They seek to do this in ways which benefit society on a national and a global scale.” Oxford University Innovation helps staff and students to apply their expertise and research for wider social and economic benefit. Their role is to help University staff and students bring the benefits of their research and expertise to create impact in wider society. They support Oxford’s researchers, staff and students, offering commercial skills and a range of specialist resources in order to maximise research impact. Income is shared with those involved according to the University’s Regulations.

AstraZeneca is an innovation-driven biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines that make a meaningful difference in healthcare. AstraZeneca discovers new medicines that are designed to improve the health and quality of life of patients around the world - medicines that are innovative, effective, and which offer added benefits such as reduced side effects or better ways of taking the treatment. AstraZeneca focuses on getting the best from every medicine they make by exploring all the ways it can be used or improved. AstraZeneca was established on April 6, 1999, in Cambridgeshire, United Kingdom.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Part of Zoetis, Inc., Zoetis Services LLC is a company headquartered in Florham Park, NJ, that discovers, develops, manufactures and sells animal health medicines and vaccines.

Sorrento Therapeutics is a development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento’s late stage pipeline include Cynviloq™ (paclitaxel in polymeric micelle formulation) currently in a registrational bio-equivalent study versus albumin-bound paclitaxel; and Resiniferatoxin (RTX),which is in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. Sorrento has one of the industry’s most diverse antibody (G-MAB®) library comprised of high-quality, fully human antibodies with a diversity of more than ten trillion (>10^16). Along with its' proprietary conjugation chemistries and novel toxins, Sorrento has all in-house capabilities to generate and develop a new generation of homogenous ADCs with well-defined drug antibody ratios (DAR) in contrast to approved ADCs, which are heterogeneous mixtures with different DARs. These differentiating characteristics may lead to improved ADC stability and pharmacokinetics while reducing off-target effects compared to existing ADCs. Sorrento's primary therapeutic focus is cancer although its products and technologies have much broader clinical applications including autoimmune disorders, metabolic diseases and infectious diseases.

Shenzhen Innosai Biotechnology Co., Ltd., established on 2017-08-07, Business scope includes general business items:technology development in biotechnology,technical consulting(law,Administrative regulations,Except for projects that are required to be approved before registration by decision of the State Council) .,The licensing program is:In vitro diagnostic reagents and biological products(Except for prophylactic biological products),R & D and sales of inspection equipment.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women��s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer��s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ.

Nanjing Genscript Co., Ltd. provides biological and pharmaceutical research services. It offers gene, peptide, protein production and purification, and antibody outsourcing services. The company was founded in 2004 and is headquartered in Nanjing, China.

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

Id Pharma Co., Ltd. manufactures and sells vaccine and gene therapy. The company utilizes its own vector platforms such as sendai virus vector in its business development, resulting in merits that are not readily available to other bio-companies. It is a workshop where scientists and engineers work together to realize their dreams of improving people's health and conquering incurable diseases by exploiting front-edge bioscience and technologies to their full potential. The firm is also a stage or base where the valuable efforts of its collaborators and supporters will come to big fruition. It believes that the promotion of creative collaborations with worldwide partners using its unique gene transfer technologies are the driving force of rapid and sure creation of valuable products and services. The company was founded on September 5, 2003 by Mamoru Hasegawa and is headquartered in Tsukuba, Japan.

SK bioscience Co., Ltd. engages in the development and distribution of bio and vaccine products. The company was founded on July 1, 2018 and is headquartered in Seongnam-si, South Korea.

BTG acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company also manufactures and commercializes therapeutic ultrasound devices, and roxwood systems, as well as develops venous thrombus management devices. British Technology Group International that began operation in 1948 became BTG in March 1995. Its headquarters is in London in the United Kingdom.

Harbour Antibodies BV engages in the production of antibodies and VH domains for therapy. The firm develops two types of human immunoglobulin gene transgenic mice such as mice that generate conventional tetrameric antibodies comprising two heavy and two light immunoglobulin chains (H2L2); and alternatively, mice that generate heavy chain only antibodies comprising two immunoglobulin heavy chains with no light chains (HCAbs). The company was founded by Frank Grosveld in 2006 and is headquartered in Rotterdam, the Netherlands.

Kunming Institute of Zoology (KIZ) (中国科学院昆明动物研究所), one of the 20 biological institutes under the Chinese Academy of Sciences (CAS), is one of China's first class zoological research institutes, located in Kunming, Yunnan province. The Institute has access to the unique and diversified animal resources of the Eastern Himalayas as well as a wide variety of the species from across Southeast Asia, the southern parts of Yunnan province being part of the Indo-Burma biodiversity hotspot. KIZ focuses on life science research, with research groups including systematic zoology, conservation biology, cytology, molecular biology, genome evolution, reproductive and developmental biology, neurobiology, immunological biology on important virus disease, zoological toxicology and primate biology.